MOTS-c + AOD-9604 Fat-Loss Research Stack
Mitochondrial-derived peptide + GH lipolytic fragment research stack — exercise-mimetic metabolic protocol without GH-axis perturbation.
The MOTS-c + AOD-9604 combination is a two-peptide metabolic research stack that approaches fat-loss biology from the mitochondrial and adipocyte-receptor level rather than the central appetite axis. MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA region of the mitochondrial genome — the first peptide discovered to originate from mitochondrial DNA and exert systemic metabolic effects [PMID:25738459]. AOD-9604 is a synthetic 15-amino-acid C-terminal fragment of human growth hormone (hGH176–191) engineered by Frank Ng and colleagues at Monash University to retain hGH's lipolytic activity while abolishing binding to the GH receptor and the consequent IGF-1-mediated effects [PMID:11713213]. Together, the two peptides provide complementary, non-overlapping metabolic signals — making this stack distinct from incretin-based or GH-secretagogue protocols.
Why pair MOTS-c with AOD-9604?
The rationale for combining these two peptides rests on the independence of their mechanisms and the complementarity of their metabolic targets. MOTS-c activates AMP-activated protein kinase (AMPK) in skeletal muscle and adipose tissue, up-regulates mitochondrial biogenesis signalling, and — as demonstrated by Changhan Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology — can translocate from the cytoplasm into the nucleus under metabolic stress to directly regulate stress-response gene expression [PMID:30017356]. AOD-9604, by contrast, acts at the β3-adrenergic receptor on mature adipocytes to stimulate lipolysis through a cyclic-AMP–dependent pathway that is entirely separate from the AMPK axis [PMID:11146367].
Crucially, neither peptide activates the GH receptor. Neither drives insulin resistance. Neither suppresses appetite through GLP-1 or GIP pathways. The combination therefore targets metabolic substrate utilisation and adipocyte lipolysis simultaneously, without the systemic hormonal re-patterning associated with either GH secretagogues or incretin mimetics. This makes the stack of particular interest in research contexts where GH-axis activation would confound results or where appetite-related endpoints are a separate variable.
Mechanism of action — each peptide
MOTS-c — mechanism of action
MOTS-c is encoded by a short open reading frame within the mitochondrial 12S rRNA gene — a discovery published by Changhan Lee in the Cohen laboratory at USC in 2015 that established a new class of mitochondrial-derived peptides (MDPs) [PMID:25738459]. Its mechanism of metabolic action involves several interconnected pathways:
- AMPK activation in skeletal muscle and fat tissue — MOTS-c phosphorylates AMPK at Thr172 in a manner that resembles the metabolic state induced by sustained aerobic exercise. In obese mouse models, this drives a shift toward fat oxidation, reduces hepatic lipid accumulation, and improves fasting blood glucose.
- Nuclear translocation under stress — Unlike most peptides, MOTS-c can enter the cell nucleus. Kim et al. (2018) demonstrated that metabolic stress (glucose restriction, exercise) causes MOTS-c to translocate from mitochondria to the nucleus, where it interacts with the antioxidant response element (ARE) and activates stress-defence gene programmes [PMID:30017356].
- Exercise-mimetic gene expression — Reynolds et al. (2021) showed in Nature Communications that circulating MOTS-c rises with exercise in both mice and humans, and that exogenous MOTS-c administration replicates the exercise-induced gene-expression signature in aged skeletal muscle [PMID:33469029]. This is the origin of the "exercise mimetic" designation.
- Insulin-sensitising effects — In diet-induced obese mice, chronic MOTS-c administration reduced fasting insulin and improved insulin tolerance test outcomes without affecting food intake, consistent with peripheral sensitisation rather than central appetite modulation [PMID:25738459].
MOTS-c has a short plasma half-life; the thrice-weekly subcutaneous dosing schedule in research protocols reflects the need to maintain consistently elevated circulating concentrations across the study window.
AOD-9604 — mechanism of action
AOD-9604 (hGH176–191) is the synthetic C-terminal fragment of human growth hormone, developed by Frank Ng and colleagues at Monash University specifically to isolate the lipolytic domain of hGH from its growth-promoting and diabetogenic domains [PMID:11713213]. The published mechanism centres on adipocyte signalling:
- β3-adrenergic receptor agonism — AOD-9604 stimulates lipolysis in mature adipocytes through a pathway dependent on the β3-adrenergic receptor (β3-AR). Heffernan et al. (2001) demonstrated in β3-AR knockout mice that AOD-9604's lipolytic effects are abolished in the absence of the receptor, distinguishing its mechanism from that of growth hormone itself [PMID:11713213].
- Cyclic-AMP–mediated fat mobilisation — Receptor activation raises intracellular cAMP, activating hormone-sensitive lipase (HSL) and driving triglyceride hydrolysis without the protein-anabolic or pro-diabetogenic effects of intact hGH.
- No GH receptor binding; no IGF-1 elevation — Multiple studies confirm that AOD-9604 does not bind the GH receptor, does not elevate serum IGF-1, and does not produce the glucose intolerance associated with supraphysiological GH [PMID:10643481]. This makes it mechanistically distinct from GHRH analogues such as Tesamorelin.
- Preferential action on visceral and subcutaneous fat — In chronic-treatment rodent studies, AOD-9604 reduced fat pad mass without affecting lean body mass or organ weight, consistent with a lipolytic rather than a global catabolic mechanism [PMID:10643481].
AOD-9604 is dosed daily in research protocols because its receptor interaction is transient; continuous receptor stimulation, particularly in a fasted metabolic state when circulating insulin is low, maximises cAMP-driven lipolytic flux.
Summarised studies on the combination
No registered human clinical trial has tested MOTS-c and AOD-9604 in co-administration. The published evidence base for each peptide is separately well-characterised in rodent models, and the rationale for combining them rests on the independence — rather than the documented synergy — of their pathways.
MOTS-c preclinical metabolic literature — The foundational Lee et al. (2015) Cell Metabolism study reported that intraperitoneal MOTS-c administration in diet-induced obese mice produced significant reductions in body weight and fat mass over 4 weeks, alongside improved glucose tolerance and reduced hepatic steatosis [PMID:25738459]. Circulating MOTS-c was found to be naturally lower in obese and insulin-resistant subjects compared to metabolically healthy controls, supporting the concept of replacement-level supplementation. The Cobb et al. (2016) Communications Biology study further established that endogenous MOTS-c levels decline with age, concurrent with declining insulin sensitivity [PMID:30271897]. Reynolds et al. (2021) extended these findings by demonstrating that exogenous MOTS-c counteracted age-related physical decline and restored exercise-responsive gene expression in aged mice [PMID:33469029].
AOD-9604 preclinical metabolic literature — The Ng et al. (2000) Hormone Research study characterised AOD-9604's lipolytic activity in fat cell assays, establishing dose-response relationships and confirming the absence of GH-receptor binding [PMID:11146367]. Heffernan et al. (1999) reported that chronic oral or subcutaneous administration in diet-induced obese mice produced sustained fat mass reduction without affecting lean mass, food intake, or serum glucose [PMID:10643481]. The 2001 β3-AR knockout study confirmed receptor specificity [PMID:11713213]. AOD-9604 reached Phase IIb clinical trials in human obesity (METAOD trials, Monash-led) where 12-week daily dosing at 1 mg oral demonstrated a modest but statistically significant reduction in body weight versus placebo; however the programme was discontinued before Phase III.
Combination rationale from parallel pathway studies — Because MOTS-c acts upstream (AMPK, mitochondrial biogenesis, glucose utilisation) and AOD-9604 acts downstream (adipocyte β3-AR, cAMP, triglyceride hydrolysis), the two signals are not competitive. AMPK activation by MOTS-c sensitises adipocytes to lipolytic signals by down-regulating lipogenic transcription, creating a permissive cellular environment for AOD-9604's β3-AR-driven fat mobilisation. This mechanistic logic — established from independent pathway studies rather than co-administration data — underpins the research stack design.
Full research protocol
The protocol below reflects dosing ranges most commonly cited across the published MOTS-c and AOD-9604 preclinical literature, with administration routes and timing consistent with research best practice for each compound.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| MOTS-c | 5–10 mg | 3x weekly SC | Pre-fasted state | 8 weeks |
| AOD-9604 | 300 µg | Daily SC fasted | Morning fasted | 8 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 |
|---|---|---|---|---|---|---|---|---|
| MOTS-c | 5 mg 3x | 10 mg 3x | 10 mg 3x | 10 mg 3x | 10 mg 3x | 10 mg 3x | — | — |
| AOD-9604 | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d | 300 µg/d |
- Loading phase (weeks 1–2): MOTS-c begins at 5 mg three times weekly to establish the AMPK-sensitising signal before escalating. AOD-9604 starts at full 300 µg daily dose throughout, as its β3-AR mechanism does not require titration.
- Active phase (weeks 2–6): Both peptides at full research doses. MOTS-c at 10 mg three times weekly maximises the exercise-mimetic and insulin-sensitising signal; AOD-9604 daily dosing sustains cAMP-driven lipolytic flux across the adipocyte compartment.
- Extended AOD-9604 phase (weeks 7–8): MOTS-c is discontinued after week 6 (consistent with the 6-week windows used in the Lee et al. studies), while AOD-9604 continues for the full 8 weeks to allow continued mobilisation of liberated free fatty acids from the metabolically sensitised adipose tissue primed by MOTS-c.
- Post-cycle observation: A 4-week wash-out is standard in metabolic research protocols before any subsequent round. Fasting glucose and insulin markers are the key endpoints to track during this window.
Reconstitution & storage notes
MOTS-c reconstitutes cleanly in bacteriostatic water at 5–10 mg/mL; the solution is stable at 2–8 °C for approximately 21 days after reconstitution. AOD-9604 reconstitutes readily at 1 mg/mL (300 µg per 0.3 mL injection volume) and is similarly stable for 21–30 days refrigerated. Both peptides are sensitive to repeated freeze-thaw cycles — aliquot into single-use volumes before freezing any stock intended for storage beyond 30 days. Protect both compounds from direct light during storage and handling.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
If you are exploring AOD-9604 metabolic stacks, you may also be interested in the Tirzepatide + Retatrutide + AOD-9604 metabolic stack, which combines incretin-driven appetite suppression with β3-AR lipolysis for a broader multi-mechanism approach, or the Tesamorelin + AOD-9604 visceral fat stack, which pairs the GHRH analogue Tesamorelin's documented visceral-fat reduction with AOD-9604's adipocyte-level lipolytic signal.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-54 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3) :516-524.e7 doi:10.1016/j.cmet.2018.06.008 · PMID: 30017356
- Reynolds JC, Lai RW, Woodhead JST, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1) :470 doi:10.1038/s41467-020-20790-0 · PMID: 33469029
- Heffernan M, Summers RJ, Thorburn A, et al.. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(12) :5182-9 doi:10.1210/endo.142.12.8522 · PMID: 11713213
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6) :274-8 doi:10.1159/000023559 · PMID: 11146367
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9) :421-9 doi:10.1016/j.molmed.2005.07.004 · PMID: 16099219
- Cobb LJ, Lee C, Xiao J, et al.. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Communications Biology. 2016;1 :1 doi:10.1038/s42003-018-0023-y · PMID: 30271897
- Heffernan MA, Thorburn AW, Fam B, et al.. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 1999;23(12) :1295-301 doi:10.1038/sj.ijo.0801088 · PMID: 10643481
Related metabolic & fat-loss stacks
Tesamorelin + AOD-9604 Visceral Fat Research Stack
GHRH analogue + GH lipolytic fragment research stack targeting visceral adipose tissue. Two-peptide protocol with documented preclinical evidence.
Tirzepatide + Retatrutide + AOD-9604 Metabolic Research Stack
Advanced metabolic / fat-loss research stack combining a dual GIP/GLP-1 agonist, triple GIP/GLP-1/glucagon agonist and a lipolytic peptide fragment. Full UK research protocol.